0000000000424178

AUTHOR

Vera Mahler

showing 13 related works from this author

Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase

2011

Background A subgroup of patients with chronic spontaneous urticaria (CU) exhibits IgE antibodies directed against autoantigens, such as thyroperoxidase (TPO). We conducted this study to investigate whether such patients with CU with IgE against TPO benefit from treatment with omalizumab, a humanized anti-IgE mAb licensed for the treatment of severe persistent allergic (IgE-mediated) asthma. Objectives We sought to assess the efficacy of omalizumab treatment in patients with CU with IgE autoantibodies against TPO. Methods In this multicenter, randomized, double-blind, placebo-controlled study patients with CU (male/female, 18-70 years of age) with IgE autoantibodies against TPO who had pers…

AdultMalemedicine.medical_specialtyAdolescentUrticariamedicine.medical_treatmentImmunologyOmalizumabOmalizumabAntibodies Monoclonal HumanizedImmunoglobulin EPlaceboAutoantigensGastroenterologylaw.inventionYoung AdultRandomized controlled triallawInternal medicineAnti-Allergic AgentsmedicineHumansImmunology and AllergyAdverse effectAgedAutoantibodiesAsthmabiologybusiness.industryAntibodies MonoclonalImmunoglobulin EMiddle Agedmedicine.diseaseAntibodies Anti-IdiotypicTolerabilityImmunologybiology.proteinFemaleAntihistaminebusinessmedicine.drugJournal of Allergy and Clinical Immunology
researchProduct

S3 Guidelines: Epicutaneous patch testing with contact allergens and drugs – Short version, Part 2

2019

Epicutaneous patch testing is the diagnostic standard for the detection of allergic contact dermatitis. The present guidelines are aimed at residents and board-certified physicians in the fields of dermatology and allergology as well as other medical specialties involved in establishing the indication for patch testing and its execution in patients with contact dermatitis and other forms of delayed-type hypersensitivity. The target audience also includes other health care providers and insurance funds. Based on a systematic literature search and a formal consensus process (S3), the guidelines were developed by dermatologists in collaboration with pediatricians, occupational medicine physici…

Occupational Medicinemedicine.medical_specialtyConsensusMEDLINETarget audienceDermatologyOccupational medicineImmunocompromised Host030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicinePregnancyHealth caremedicineHumansHypersensitivity DelayedPediatriciansChildAdverse effectAllergic contact dermatitisbusiness.industryAllergensPatch Testsmedicine.disease3. Good healthTest (assessment)Family medicineDermatitis Allergic ContactPractice Guidelines as TopicFemaleNursing StaffbusinessContact dermatitisDermatologistsJDDG: Journal der Deutschen Dermatologischen Gesellschaft
researchProduct

The concentration of para-phenylenediamine (PPD) for routine patch testing in a standard series needs to be redefined

2005

medicine.medical_specialtyPediatricsDose-Response Relationship Drugbusiness.industryDermatologyPatch TestsPhenylenediaminesPara phenylenediamineDermatologyPatch testing030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineGermany030220 oncology & carcinogenesisDermatitis Allergic ContactmedicineHumansImmunology and AllergyColoring AgentsbusinessContact Dermatitis
researchProduct

Patch testing in children--recommendations of the German Contact Dermatitis Research Group (DKG).

2007

Summary Allergic contact dermatitis occurs frequently in children. Patch testing is needed to identify the responsible allergens and should be performed in children. We recommend a panel of 12 contact allergens as a standard series in children from 6–12 years. Four additional contact allergens should be tested in case of a positive history or suggestive clinical picture. For patch testing in children, the allergens should be applied for 24 hours and the readings should be performed at 48 and 72 hours. Standardized patch testing makes it possible to systematically investigate allergic contact dermatitis and identify relevant allergens in children.

medicine.medical_specialtyDermatitisDermatologyPediatricsPatch testing030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineimmune system diseases030225 pediatricsGermanyotorhinolaryngologic diseasesmedicineHumansContact allergensPractice Patterns Physicians'Allergic contact dermatitisbusiness.industryrespiratory systemPatch Testsmedicine.diseaseDermatologyrespiratory tract diseases3. Good healthDermatitis Allergic ContactPractice Guidelines as TopicbusinessContact dermatitisJournal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
researchProduct

Technical standards in allergen exposure chambers worldwide - an EAACI Task Force Report

2021

Allergen exposure chambers (AECs) can be used for controlled exposure to allergenic and non-allergenic airborne particles in an enclosed environment, in order to (i) characterize the pathological features of respiratory diseases and (ii) contribute to and accelerate the clinical development of pharmacological treatments and allergen immunotherapy for allergic disease of the respiratory tract (such as allergic rhinitis, allergic rhinoconjunctivitis, and allergic asthma). In the guidelines of the European Medicines Agency for the clinical development of products for allergen immunotherapy (AIT), the role of AECs in determining primary endpoints in dose-finding Phase II trials is emphasized. A…

Allergen immunotherapymedicine.medical_specialtyAllergyImmunologytechnical standardsmedicineImmunology and AllergyHumansallergen exposure chambersIntensive care medicineCOVID-19 ; allergen exposure chambers ; clinical trials ; Allergie ; technical standards ; allergen immunotherapyField exposureclinical trialsTask forcebusiness.industryCOVID-19Technical informationAllergic asthmaAllergensrespiratory systemmedicine.diseaseRhinitis AllergicAsthmaClinical trialDesensitization Immunologicallergen immunotherapyPollenALLERGEN EXPOSUREbusiness
researchProduct

Chromated metal products may be hazardous to patients with chromate allergy.

2009

Background:  Hidden allergen exposure may contribute to persistence and relapse of chromate dermatitis. According to case reports, chromated metal products, such as screws, fittings, etc., may be relevant allergen sources for patients sensitized to chromate. Objectives:  To examine concomitant patch test reactivity to potassium dichromate 0.5% petrolatum (pet.) and three different types of chromated metal rings. Patients/Methods:  Patients with proven or suspected chromate allergy were patch tested with potassium dichromate 0.5% pet. and three different types of chromated metal rings (yellow, olive, and black). Hexavalent chromium Cr(VI) release from the patch tested rings was chemically an…

AdultChromiumMaleAllergyDermatologyMetal030207 dermatology & venereal diseases03 medical and health scienceschemistry.chemical_compound0302 clinical medicineChromium CompoundsGermanymedicineImmunology and AllergyHumansIn patientHexavalent chromium030223 otorhinolaryngologyPotassium dichromateChromate conversion coatingMetallurgyPatch testAllergensMiddle AgedPatch Testsmedicine.disease3. Good healthchemistryvisual_artDermatitis Allergic Contactvisual_art.visual_art_mediumFemalePotassium DichromateContact dermatitisNuclear chemistryContact dermatitis
researchProduct

Late reactions to patch test preparations with reduced concentrations of p-phenylenediamine : a multicentre investigation of the German Contact Derma…

2011

Background. p-Phenylenediamine (PPD) 1% in petrolatum has been shown in a prospective study to elicit late reactions in 1.5% of routine patch tests, which may be indicative of patch test sensitization. Objectives. To assess the frequency of late reactions to reduced PPD patch test concentrations. Methods. In 1838 patients, PPD was tested at three concentrations (0.5% pet., group I; 0.4% pet., group II; and 0.35% pet., group III). Patch tests were read on D1 (D2) to D3 (D4); additional late readings were performed on D7, D14, and D21. Patients who were not able to return for all scheduled late readings were telephoned on D7, D14, and D21, and questioned about a reaction at the patch test sit…

AdultMalemedicine.medical_specialtyAllergyTime FactorsMedizinDermatologyPhenylenediaminesGastroenterology030207 dermatology & venereal diseases03 medical and health scienceschemistry.chemical_compoundYoung Adult0302 clinical medicineImmunopathologyInternal medicineImmunology and AllergyMedicineHumans030212 general & internal medicineProspective cohort studySensitizationbusiness.industryPatch testp-PhenylenediamineMiddle AgedPatch Testsmedicine.disease3. Good healthSurgerymedicine.anatomical_structurechemistryPatch test sensitizationDermatitis Allergic ContactFemalebusinessContact dermatitis
researchProduct

S2k guidelines for the use of topical preparations on the skin

2018

The present guidelines are aimed at dermatology residents and board-certified dermatologists as well as policymakers and insurance companies. Developed by dermatologists in collaboration with pharmacists using a formal consensus process (S2k), they include general aspects with respect to pharmacokinetics and regulatory terminology. Recommendations are provided on the various indications for extemporaneous preparations and their quality assurance. The importance of pharmaceutical vehicles and problems associated with substituting one vehicle for another are discussed. The guidelines include criteria for choosing a suitable pharmaceutical vehicle and for specific aspects in terms of treatment…

030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineRisk analysis (engineering)Process (engineering)business.industry030220 oncology & carcinogenesisDermatologyPharmaceutical VehiclesExtemporaneous preparationsbusinessQuality assuranceTerminologyJDDG: Journal der Deutschen Dermatologischen Gesellschaft
researchProduct

Psoriasis predisposition and occupational triggering factors in the appraisal of occupational medical expertises

2014

Summary Background Psoriasis is an immune-mediated disease with a genetic background. Local psoriatic changes can be triggered by exogenous mechanical or irritant factors. Causative occupational factors have to be distinguished from the spontaneous course of psoriasis in occupational medical evaluations. The objective of this work is to demonstrate the medico-legal grounds for a homogenous assessment. Patients and methods The presented recommendations were developed in a working group for Occupational and Environmental Dermatology (ABD) and the German contact dermatitis group (DKG) of the German Dermatologic Society (DDG) based on the German medico-legal framework. Results Causality between…

medicine.medical_specialtyRehabilitationbusiness.industrymedicine.medical_treatmentDermatologyGuidelineDiseasemedicine.diseaseCausalitylanguage.human_language3. Good healthSurgeryGermanExpert witnessPsoriasisFamily medicinemedicinelanguagePosition paperbusinessJDDG: Journal der Deutschen Dermatologischen Gesellschaft
researchProduct

S2k-Leitlinie zum Gebrauch von Präparationen zur lokalen Anwendung auf der Haut (Topika)

2018

Diese Leitlinie richtet sich an Assistenz- und Facharzte der Dermatologie sowie an Kostentrager und politische Entscheidungsgremien. Die Leitlinie wurde im formellen Konsensusverfahren (S2k) von Dermatologen unter Einbindung von Apothekern erstellt. Die Leitlinie stellt allgemeine Aspekte der Pharmakokinetik sowie der regulatorischen Begrifflichkeiten dar. Es werden Empfehlungen zur Indikation von Magistralrezepturen sowie deren Qualitatssicherung gegeben. Die Bedeutung der galenischen Grundlagen und die Problematik bei einer Substitution gegeneinander verschiedener Grundlagen werden dargestellt. Die Leitlinie umfasst Kriterien zur Auswahl einer adaquaten Grundlage sowie spezifische Aspekte…

Gynecology030207 dermatology & venereal diseases03 medical and health sciencesmedicine.medical_specialty0302 clinical medicinebusiness.industry030220 oncology & carcinogenesismedicineDermatologybusinessJDDG: Journal der Deutschen Dermatologischen Gesellschaft
researchProduct

Management of anaphylaxis due to COVID-19 vaccines in the elderly

2021

Submitted by (omml@ubi.pt) on 2021-07-05T10:47:24Z No. of bitstreams: 1 2021_Bousquet J_A_COVID anaphylaxis.pdf: 12561118 bytes, checksum: 2f801ee76ad2cb3cbdaa02ffabea8e09 (MD5) Approved for entry into archive by Pessoa (pfep@ubi.pt) on 2021-07-05T10:49:11Z (GMT) No. of bitstreams: 1 2021_Bousquet J_A_COVID anaphylaxis.pdf: 12561118 bytes, checksum: 2f801ee76ad2cb3cbdaa02ffabea8e09 (MD5) Rejected by Pessoa (pfep@ubi.pt), reason: Rever os nomes dos autores. Depois da correção é só voltar a submeter. on 2021-07-05T10:54:19Z (GMT) Submitted by (omml@ubi.pt) on 2021-07-05T11:52:24Z No. of bitstreams: 1 2021_Bousquet J_A_COVID anaphylaxis.pdf: 12561118 bytes, checksum: 2f801ee76ad2cb3cbdaa02ffab…

MaleAllergyPediatricsEaaci Position PaperCOVID-19 vaccinesolder (adultsGUIDELINES0302 clinical medicine[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesMedicine and Health SciencesImmunology and AllergyMedicine030212 general & internal medicineComputingMilieux_MISCELLANEOUSGeriatricsMESH: AgedRISKVaccines[SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseasespeople)EPINEPHRINEEpinephrine[SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/VirologyCOVID -19 vaccinesAnaphylaxismedicine.drugolder (adults/people)medicine.medical_specialtyCoronavirus disease 2019 (COVID-19)MESH: Covid-19MESH: EpinephrineImmunologyadrenaline; anaphylaxis; COVID-19 vaccines; older (adults/people); Aged; COVID-19 Vaccines; Epinephrine; Humans; Male; SARS-CoV-2; Anaphylaxis; COVID-19Settore MED/10 - Malattie Dell'Apparato Respiratorio03 medical and health sciences[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemDiabetes mellitusAnaphylaxis/etiologyanaphylaxisHumansMESH: SARS-CoV-2[SDV.MP.PAR]Life Sciences [q-bio]/Microbiology and Parasitology/ParasitologyCOVID‐19 vaccinesOlder - Adults/peopleAsthmaAgedMESH: Humansadrenalinebusiness.industrySARS-CoV-2adrenaline anaphylaxis COVID-19 vaccines older (adults/people)COVID-19medicine.diseaseObesity[SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/BacteriologyMESH: MaleMESH: AnaphylaxisOlder3121 General medicine internal medicine and other clinical medicinebusinessMESH: Covid-19 vaccines030215 immunologyAllergy
researchProduct

Recommendations for photopatch testing by the Photopatch Test Working Group of the German Contact Dermatitis Research Group (DKG).

2018

medicine.medical_specialtybusiness.industryDermatitis PhotoallergicPhotopatch testDermatologyPatch Testsmedicine.diseaseDermatologylanguage.human_languageGerman030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineGroup (periodic table)030220 oncology & carcinogenesislanguageMedicineHumansbusinessContact dermatitisJournal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
researchProduct

S3 guidelines: Epicutaneous patch testing with contact allergens and drugs – Short version, Part 1

2019

Epicutaneous patch testing is the diagnostic standard for the detection of allergic contact dermatitis. The present guidelines are aimed at residents and board-certified physicians in the fields of dermatology and allergology as well as other medical specialties involved in establishing the indication for patch testing and its execution in patients with contact dermatitis and other forms of delayed-type hypersensitivity. The target audience also includes other health care providers and insurance funds. Based on a systematic literature search and a formal consensus process (S3), the guidelines were developed by dermatologists in collaboration with pediatricians, occupational medicine physici…

Occupational Medicinemedicine.medical_specialtyConsensusMEDLINETarget audienceGuidelines as TopicDermatologyPatch testingOccupational medicineImmunocompromised Host030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicinePregnancyHealth caremedicineHumansHypersensitivity DelayedPediatriciansChildAllergic contact dermatitisbusiness.industryAllergensPatch Testsmedicine.diseaseTest (assessment)Family medicineDermatitis Allergic ContactFemaleNursing StaffbusinessContact dermatitisDermatologistsJDDG: Journal der Deutschen Dermatologischen Gesellschaft
researchProduct